Company news
IDEAYA Biosciences, Inc. news in 2024
IDEAYA Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
December 28, 2024
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
December 16, 2024
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
December 15, 2024
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
December 10, 2024
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
December 9, 2024
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
December 8, 2024
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
December 1, 2024
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
November 17, 2024
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
November 11, 2024
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
November 10, 2024
Correction: IDEAYA Biosciences, Inc.
November 3, 2024
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
October 27, 2024
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
October 24, 2024
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
October 3, 2024
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
September 22, 2024
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
September 21, 2024
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
September 17, 2024
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 25, 2024
IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 5, 2024
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
July 30, 2024
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
July 28, 2024
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
July 10, 2024
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
July 8, 2024
IDEAYA Announces Pricing of Public Offering
July 8, 2024
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
July 7, 2024
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
July 4, 2024
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
June 24, 2024
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
June 23, 2024
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
June 2, 2024
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
May 28, 2024
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
May 27, 2024
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
April 30, 2024
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
April 23, 2024
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
April 21, 2024
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
March 31, 2024
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
March 11, 2024
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
March 3, 2024
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
February 19, 2024
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
January 31, 2024
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
January 6, 2024
Decks in 2024
- Investor Presentation (July 2024)
Investor deck · 43 slides · Jul 8, 2024
- Investor Presentation (May 2024)
Investor deck · 38 slides · May 7, 2024